Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521 Overall, 142 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PHILADELPHIA — A novel therapy targeting human ...

Egret Therapeutics, Inc. ("Egret"), a clinical-stage biotechnology company developing novel immune-modulatory therapies for secondary inflammation following traumatic and ischemic disorders, today ...

Patients were intravenously dosed with balstilimab 3 mg/kg once every 2 weeks and zalifrelimab 1 mg/kg once every 6 weeks, for up to 24 months. The primary end point was objective response rate (ORR, ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Move over PD-1, your time has passed. At least, that’s the sense from IQVIA’s latest report, which suggests development of immuno-oncologics such as PD-1/PD-L1 checkpoint inhibitors has started to ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...

Eli Lilly has been talking up a “disruptive” pricing strategy for its Innovent Biologics-partnered PD-1 inhibitor Tyvyt in the U.S. Now, we have an idea of what the company means. But whether it’s ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in bladder cancer, positioning the Big Pharma to file for approval of an ...